With the FDA decision on Biogen's Aducanumab | IONS Message Board Posts


Ionis Pharmaceuticals, Inc.

  IONS website

IONS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  61597 of 61606  at  6/13/2021 7:51:02 AM  by

Mabel


 In response to msg 61596 by  riverwalk
view thread

Re: With the FDA decision on Biogen's Aducanumab

 you may be correct that the strong negative Biogen reaction might cause a boomerang effect on future drug candidates but as i said, if i was Roche i would initiate a conversation on their pulled Huntington's drug. 
 
BIIB's outrageous pricing will not do the industry on the whole any good.  The reality is that only a small percentage of patients would drop 56k out of pocket on a drug that has questionable efficacy.  Insurance coverage including Medicare and Medicaid will determine the commercial success of Aduhelm.   


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0  
   Views: 0 [1]
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
61598 Re: With the FDA decision on Biogen's Aducanumab riverwalk 0 6/13/2021 8:04:51 PM
61599 Re: With the FDA decision on Biogen's Aducanumab Bigbiotechbull 0 6/14/2021 12:18:43 AM


Financial Market Data provided by
.
Loading...